Drug maker, Ranbaxy Laboratories has received final approval from the US Food and Drug Administration (USFDA) to market and manufacture Ramipril capsules in the strengths of 5mg and 10 mg respectively.

Ramipril is indicated in patients 55 years or older and helps to reduce the risk of myocardial infarction, stroke or death from cardiovascular causes.

Recently, the drug maker had got an approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Quinapril Hydrochloride & Hydrochlorothiazide (Quinapril + HCTZ) tablets, an ACE inhibitor and is used to treat high blood pressure.

Shares of the company gained Rs 2.8, or 1.98%, to trade at Rs 144.10. The total volume of shares traded was 155,589 at the BSE (10.09 a.m., Monday).